The world’s first malaria vaccine called RTS,S or Mosquirix on 24 July 2015 got approval from European Medicines Agency (EMA).
The vaccine was licensed for use on babies aged between 6 weeks and 17 months in Africa, which is at the highest risk of the mosquito-borne disease.
The vaccine developed by British drugmaker GlaxoSmithKline in partnership with the PATH Malaria Vaccine Initiative, would be the first licensed human vaccine against a parasitic disease and could help prevent millions of cases of malaria.
The vaccine is also part-funded by the Bill & Melinda Gates Foundation and it was in development since 1987 under a team of researchers led by Joe Cohen, a GSK scientist.
The vaccine was approved despite the dampened results released in 2011 and 2012. The results showed that it only reduced episodes of malaria in babies aged 6-12 weeks by 27 percent, and by around 46 percent in children aged 5-17 months.
In 2013, Malaria killed an estimated 58400 people, of which majority were from the sub-Saharan Africa. About 80 percent deaths were in children under the age of five.